Shire PLC (LON:SHP)‘s stock had its “overweight” rating reissued by JPMorgan Chase & Co. in a research report issued on Friday, May 19th. They currently have a GBX 6,000 ($78.05) price target on the biopharmaceutical company’s stock. JPMorgan Chase & Co.’s price target would indicate a potential upside of 28.99% from the stock’s current price.

Several other equities research analysts have also recently issued reports on the stock. Credit Suisse Group AG reaffirmed an “outperform” rating and set a GBX 5,400 ($70.25) price target on shares of Shire PLC in a research note on Wednesday, April 19th. Barclays PLC initiated coverage on shares of Shire PLC in a research note on Wednesday, March 8th. They set an “overweight” rating and a GBX 6,500 ($84.56) price target on the stock. Goldman Sachs Group Inc reaffirmed a “conviction-buy” rating and set a GBX 6,800 ($88.46) price target on shares of Shire PLC in a research note on Thursday, April 27th. Berenberg Bank reaffirmed a “buy” rating on shares of Shire PLC in a research note on Wednesday, April 12th. Finally, HSBC Holdings plc reaffirmed a “hold” rating and set a GBX 4,550 ($59.19) price target on shares of Shire PLC in a research note on Wednesday, May 3rd. One equities research analyst has rated the stock with a sell rating and seventeen have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of GBX 6,108.38 ($79.46).

Analyst Recommendations for Shire PLC (LON:SHP)

Shares of Shire PLC (LON:SHP) traded down 1.825665% during trading on Friday, reaching GBX 4657.087402. 3,658,827 shares of the company’s stock were exchanged. The stock has a 50 day moving average price of GBX 4,635.06 and a 200-day moving average price of GBX 4,662.20. Shire PLC has a 52 week low of GBX 2,707.19 and a 52 week high of GBX 5,377.00. The stock’s market capitalization is GBX 42.25 billion.

ILLEGAL ACTIVITY NOTICE: “Shire PLC (SHP) Given “Overweight” Rating at JPMorgan Chase & Co.” was originally posted by American Banking News and is the sole property of of American Banking News. If you are viewing this piece of content on another website, it was stolen and republished in violation of U.S. and international trademark and copyright law. The original version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/05/28/shire-plc-shp-given-overweight-rating-at-jpmorgan-chase-co.html.

In other news, insider William Burns acquired 136 shares of the company’s stock in a transaction dated Friday, March 31st. The shares were bought at an average price of GBX 4,742 ($61.69) per share, for a total transaction of £6,449.12 ($8,389.64).

About Shire PLC

Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.

Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.